Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$273.00
-6.00 (-2.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-701.9M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.5B
P/E
42.7x
↑EV/EBITDA
15.2x
↑ROE
0.6%
↑Gross Margin
46.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.4%
FCF CAGR
—
FCF margin
-14.0%
FCF / Net income
-16.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.79B · net income $64.4M · FCF $-1.09B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.79B | $7.79B | $7.74B | $8.66B | $8.38B |
| Net Income | $64.4M | $64.4M | $109.0M | $138.3M | $238.5M |
| EBITDA | $438.7M | $438.7M | $571.0M | $657.9M | $755.5M |
| EPS | 1.85 | 1.85 | 3.13 | 3.98 | 6.87 |
| Gross Margin | 46.5% | 46.5% | 46.5% | 47.4% | 52.0% |
| Operating Margin | -5.9% | -5.9% | -2.5% | 1.6% | -0.2% |
| Net Margin | 0.8% | 0.8% | 1.4% | 1.6% | 2.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 4.30 | 4.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.09B | $-1.09B | $-701.9M | $420.8M | $-1.2M |
| Returns | |||||
| ROE | 0.6% | 0.6% | 0.9% | 1.2% | 2.1% |
| Valuation | |||||
| P/E | 42.72 | 42.72 | 74.76 | 60.80 | 41.63 |
| EV/EBITDA | 15.16 | 15.16 | 8.03 | 7.08 | 9.03 |
| P/B | 0.82 | 0.82 | 0.68 | 0.71 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -10.6% | 3.3% | — |
| EPS Growth | -40.9% | -40.9% | -21.4% | -42.1% | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
135.7%
EPS terminal req.
$24.22
Spread vs growth
-176.6%
5Y implied EPS CAGR
73.8%
EPS terminal req.
$29.31
Spread vs growth
-114.7%
10Y implied EPS CAGR
38.3%
EPS terminal req.
$47.21
Spread vs growth
-79.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.5%
Start / end P/E
94.9x → 147.6x
EPS bridge
3.13 → 1.85
Residual
-22.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.